Sugi Predict

Sugi Predict / Targets / SCN9A

SCN9A

Sodium channel protein type 9 subunit alpha · Q15858 · SCN9A on Sugi Atlas →

265,192 patent compounds predicted against SCN9A, 106,741 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL121418 SCHEMBL121418 0.53 16/20
SCHEMBL121389 SCHEMBL121389 0.70 15/20
SCHEMBL121650 SCHEMBL121650 0.54 15/20
SCHEMBL147558 SCHEMBL147558 0.55 14/20
SCHEMBL121689 SCHEMBL121689 0.72 13/20
SCHEMBL121474 SCHEMBL121474 0.68 13/20
SCHEMBL122571 SCHEMBL122571 0.67 13/20
SCHEMBL146859 SCHEMBL146859 0.66 12/20
SCHEMBL86128 SCHEMBL86128 0.56 11/20
SCHEMBL120345 SCHEMBL120345 0.54 10/20
SCHEMBL73052 SCHEMBL73052 0.53 10/20
SCHEMBL71183 SCHEMBL71183 0.50 10/20
SCHEMBL17015 SCHEMBL17015 0.47 10/20
Lamotrigine Lamotrigine (SCHEMBL35439) 1.00 9/20
SCHEMBL71344 SCHEMBL71344 0.53 9/20
SCHEMBL71459 SCHEMBL71459 0.53 9/20
SCHEMBL50868 SCHEMBL50868 0.55 8/20
SCHEMBL51250 SCHEMBL51250 0.55 8/20
SCHEMBL70037 SCHEMBL70037 0.50 8/20
SCHEMBL150993 SCHEMBL150993 0.52 6/20

Clinical trials — most relevant to SCN9A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations PHASE4COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Suzetrigine in Total Hip Arthroplasty PHASE3RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome PHASE1/PHASE2COMPLETED
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome PHASE1/PHASE2RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 EARLY_PHASE1COMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
fMRI-study in Patients With Small Fiber Neuropathy nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual Developmental Disorders nanRECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom nanRECRUITING
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Treatment of Gait Disorders in Children With Dravet Syndrome nanCOMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Single Gene Polymorphism and the Success Rate of Inferior Alveolar Nerve Block nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
Piezo2-related Arthrogryposis & physiopathOLOgy 3 nanNOT_YET_RECRUITING
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity nanUNKNOWN
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation nanRECRUITING
Heart and Skeletal Muscle Problems in Neuroacanthocytosis nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SCN9A binder may also engage these)

ProteinNameSimilarity
O08562 — 1.000 O08562 →
Q28644 — 1.000 Q28644 →
Q62205 — 1.000 Q62205 →
A2APX8 — 1.000 A2APX8 →
SCN2A Sodium channel protein type 2 subunit alpha 1.000 landscape →
P04775 — 1.000 P04775 →
SCN3A Sodium channel protein type 3 subunit alpha 1.000 landscape →
O88420 — 0.999 O88420 →
P02719 — 0.998 P02719 →
P08104 — 0.998 P08104 →
A2ASI5 — 0.998 A2ASI5 →
SCN8A Sodium channel protein type 8 subunit alpha 0.998 landscape →
P04774 — 0.998 P04774 →
B1AWN6 — 0.997 B1AWN6 →
SCN1A Sodium channel protein type 1 subunit alpha 0.997 landscape →
Q9WTU3 — 0.996 Q9WTU3 →
P15390 — 0.994 P15390 →
Q6QIY3 — 0.994 Q6QIY3 →
Q62968 — 0.994 Q62968 →
Q2XVR7 — 0.993 Q2XVR7 →
Q2XVR3 — 0.993 Q2XVR3 →
Q20JQ7 — 0.992 Q20JQ7 →
Q2XVR6 — 0.991 Q2XVR6 →
P15389 — 0.991 P15389 →
Q9ER60 — 0.991 Q9ER60 →
Q9R053 — 0.991 Q9R053 →
Q9JJV9 — 0.991 Q9JJV9 →
Q28371 — 0.990 Q28371 →
SCN10A Sodium channel protein type 10 subunit alpha 0.990 landscape →
O88457 — 0.990 O88457 →